Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 23Leukemia, Myeloid, Acute 23Neoplasm Metastasis 19Breast Neoplasms 19Pancreatic Neoplasms 16Multiple Myeloma 14Melanoma 13Prostatic Neoplasms 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Burkitt Lymphoma 12Lymphoma 11Colorectal Neoplasms 11Urinary Bladder Neoplasms 10Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Mouth Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Endometrial Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Oropharyngeal Neoplasms 7Myelodysplastic Syndromes 7Laryngeal Neoplasms 7Fallopian Tube Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Neuroblastoma 6Nasopharyngeal Carcinoma 6

Interventions

cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2trastuzumab deruxtecan 1avelumab 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urethral Neoplasms × Specimen Handling × 30 days × Clear all
NCT05092958 2026-06-12

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
654 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡